Larix BioScience, LLC is a protein engineering and drug development company founded out of and presently operating at PRI.

Absalus Inc. was founded at PRI to develop “Superhumanization” technology developed by Dr. Jeff Foote. Absalus merged with Australian company EvoGenix in 2005, just prior to the EvoGenix IPO. In 2007 EvoGenix merged with PepTech Ltd. creating the largest Australian biopharma company subsequently renamed Arana Therapeutics. In 2009, Arana was acquired by Cephalon and then in 2011 Cephalon was acquired by Teva for $6.8B.

Adamas Pharmaceuticals was founded out of PRI to develop first generation nitroadamantane compounds for Alzheimer’s disease. Adamas was acquired in 2021 by Supernus Pharmaceuticals.

CTS Biopharma, LLC is a PRI-founded company focused on modulating activities of the novel cardiotonic steroid, marinobufagenin (MBG).

CytoMag, LLC was founded with scientists and novel technology “MagSifter” from Stanford.

Dyax, Inc. acquired PRI-founded company Target Quest in 1999 prior to its IPO in 2000. Dyax Corp. was a biopharmaceutical company, that developed treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. Dyax was acquired by Shire in 2015 for $5.9B.

Extend Pharma, LLC was a PRI-based company developing a novel antibody conjugation technology.

Fibralign Corp. was co-founded at PRI. Fibralign has pioneered a novel collagen-based technology. see https://www.fibralignbio.com/about/

Galaxy Biotech, LLC was co-founded by antibody engineering pioneer, Dr. Cary Queen and former Genentech antibody director, Dr. Jin Chen. Galaxy generated and licensed a number of therapeutic antibodies to Millenium/Takeda (HGF), Roche (FGF), Five Prime/Amgen (FGF-r) and others. PRI continues to practice the “Gold Standard” antibody humanization technology that Dr. Queen developed. This technology served as the basis for the co-founding of Protein Design Labs, one of the early (and quite successful!) antibody engineering companies.

Geyser Biopharma, LLC was a PRI-founded company developing a KCNK9 antibody for various cancers.

PRI licensed its LPS-binding protein project to Igenex. Igenex was acquired in 2015 for ~$40M.

Integrigen, Inc. was an an antibody engineering company developing a novel Abzyme technology.

Kalabios, Inc. (originally Horizon Biotechnology, Inc.) was spun out of PRI to develop a novel antibody engineering technology based on an interaction trap. Current name of public company that acquired Horizon is Humanigen Inc. see Website: humanigen.com

Lucidant Polymers, Inc. is a PRI-based company that manufactures novel polymers for capillary electrophoresis and other separation applications. see Lucidant.com

Life Science Angels, Inc. (LSA) is the premier USA angel investment group. Since shortly after inception, LSA has been based at PRI. Dr. Larrick served as head of BioPharma screening for many years and continues to review potential angel investment opportunities. see www.lifescienceangels.com

MagArray Inc. was founded and initially incubated at PRI. MagArray is developing a magnetic nanosensor technology that originated at Stanford. See www.Magarray.com

Exited to Corbus Pharmacueticals (NASDAQ: CRBP) in 2021.

Nepenthe, LLC is a PRI-based company developing a novel CD79 antibody for various immunological diseases.

The initial reduction to practice of the technology that formed the basis for NuGen Technologies was carried out at PRI in 2000.

PanoLife Products, Inc. was founded at PRI in the 1990s to commercialize various nutriceutical products.

Planet Biotechnology, Inc. was founded out of PRI int he 1990s to develop transgenic plants as a “bioreactor” to make antibodies and antibody-fusion proteins. see www.planetbiotechnology.com

Pyrogenyx was a PRI-founded company developing a novel pyrophosphate therapy for extra-osseous calcification. Presently, this technology is being developed by PXE International.

Quality Control Labs, Inc. was a QA/QC lab for biopharmaceutical drug development that was founded out of PRI in the 1990s.

Based at PRI, the Regenerative Sciences Institute (RSI) is a 501(c)3 non-profit organization that seeks to develop regenerative therapies for aging. A large number of interns have been trained by Dr. Andrew Mendelsohn and his staff. Website: regensci.org

Rotifer Biopharma, LLC is a PRI-founded company focused on modulation of GDF15.

Theron Pharmaceuticals, Inc. was incubated at PRI and initially funded by Life Science Angels. Theron developed a best-in-class muscarinic 3 antagonist subsequently outlicensed.

TranTarget, Inc. is developing bispecific antibodies to direct activated CD3+ T lymphocytes to specifically kill cancer cells.

Two-Three Biopharma, LLC was a PRI-founded company developing a rhIL-2-antibody fusion (mAbKine) for immuno-oncology.

Velocity Pharmaceutical Development (VPD) was a CMEA/Presidio Partners funded development company with laboratories based at PRI. (Dr. Larrick was a managing director of VPD). Website: VPD.net

Vitesse Biologics was a Velocity Pharmaceutical development/Mayo Clinica/Baxalta/Shire investment company which has laboratories at PRI. (Dr. Larrick was a managing director).

WntGen, LLC, was founded at PRI to develop an LRP6 antibody for fibrotic diseases.

Xagros, Inc. was founded at PRI to develop a microsensor technology developed at Stanford.

X37 is an AI-machine learning based drug development company co-founded out of Velocity Pharmaceutical Development with laboratory and office space at PRI. see Website: X37.ai